

MARA Rating®

COMPLIMENTARY REPORT ©MARA Rating Company AG® All rights reserved.

Fremanezumab

A Market Access Risk Assessment (MARA Rating®) of Fremanezumab for preventing migraine.



MARA
RATING COMPANY

MARKET ACCESS
RISK ASSESSMENT


MARA Rating® of Fremanezumab in preventing migraine.

Market Access Score

81/100



As of: **February 22**



Assets rated A have historically achieved favorable reimbursement outcomes across a range of payer settings. Evidence packages are generally robust, though some domains may remain sensitive to HTA interpretation. This rating indicates positioning above the reimbursement threshold, where decisions more frequently concern access conditions rather than overall eligibility. Historical outcomes in this range show limited structural barriers, with some variability by market and system.

The **industry-standard MARA Rating®** synthesizes 10 payer-relevant evidence domains into a single market access risk score (A++ to C), calibrated against historical HTA outcomes.

MARA Rating® Heatmap for Fremanezumab

Clinical and Patient Value	Clinical Effectiveness	Safety & Adverse Events	Health-Related Quality of Life (HRQoL)
Evidence and HTA Fit	Comparator Selection	Patient Population & subgroups	Evidence Quality & Robustness
Economics and System Integration	Cost-Effectiveness	Resource Use and Cost	Care Pathway Integration

What You Unlock in the Full MARA Report

Why this asset clears the reimbursement threshold

Detailed interpretation explaining which strengths support access and where evidence or economics introduce payer sensitivity.

Benchmarking vs therapeutic-area norms

Comparison clarifying whether this access profile is robust relative to peers or closer to the lower boundary of the strong reimbursement range.

Remaining uncertainties influencing outcomes

Identification of variables that may affect pricing, scope, or conditions of reimbursement, particularly across different HTA bodies or payer systems.

Comparative radar and heatmap views

Visual analysis highlighting where this asset diverges from stronger and weaker comparators, and how similar patterns have historically played out in HTA decisions.

The full MARA Report explains why this asset sits at its current rating level, which variables typically determine reimbursement outcomes at this level, and how comparable assets have performed in real reimbursement decisions.

Visit mararating.com to access the full report.

*Disclaimer: The MARA Rating® is an independent opinion of a drug's market access/pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. All opinions, analyses, and recommendations are statements of opinion, not statements of fact, and are supplied "as-is" without warranty of any kind, express or implied, including accuracy, completeness, or fitness for any particular purpose. Users assume full responsibility for their decisions and any consequences thereof. MARA Rating Company AG expressly disclaims all liability for any outcomes arising from the use of, or actions taken based on, this report. Report may contain public sector information and others. All brand names are the property of their respective owners. For reimbursement & HTA professionals only—Not for patients, prescribers or the general public. **Rights & Display.** © MARA Rating Company AG. Viewing permitted. Reproduction, reprinting, redistribution, scraping, or public display of any MARA rating, badge, letter grade, chart, or the "Primary line" in marketing, IR, PR, sales, paid media, conference materials, or websites is prohibited without a valid MARA Display License. Non-licensees may link to this page/report but may not copy, repost, or restyle our content. Use must include the as-of date, our one-line explainer, and no edits to wording or artwork. No composite marks (do not combine the MARA badge with other logos/seals). No implication of MARA's endorsement of efficacy, safety, price, or any transaction. "MARA", "MARA Rating", and the MARA badge are trademarks of MARA Rating Company AG. Academic excerpt: up to 50 words of text (no badge/graphics) may be quoted with clear attribution and link. No commercial use. Misuse or corrections: contactsales@mararating.com.